Reply to Pasqualotto and Sukiennik by Senn, Laurence et al.
CORRESPONDENCE • CID 2008:47 (15 July) • 293
given for approximately one-fifth of epi-
sodes of febrile neutropenia. Interestingly,
recovery of neutropenia occurred within
a median of 11 days after fever onset, and
peak b-glucan levels for IC occurred after
a median of 12 days after fever onset. He-
patosplenic candidosis caused the presen-
tation of all but 1 case of IC. Because flu-
conazole is not active against Aspergillus
species, these data suggest that the use of
fluconazole might have influenced the
sensitivity of b-glucan testing (only 1 case
of candidemia was detected) and the time
for the b-glucan test to reach its zenith.
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Reply to Pasqualotto
and Sukiennik
To the Editor—We thank Pasqualotto
and Sukiennik [1] for their interesting
comments regarding our publication
about 1,3-b-d-glucan (BG) antigenemia
for the early diagnosis of invasive asper-
gillosis (IA) and candidiasis (IC) in neu-
tropenic patients [2]. Because of the mor-
bidity and mortality of these infections,
early antifungal therapy is critical. A non-
invasive monitoring tool that detects both
Aspergillus and Candida species is an at-
tractive approach. A positive result of the
screening test may trigger further inves-
tigations and preemptive antifungal ther-
apy. Our results suggest that BG may fulfill
this goal. Although BG does not differ-
entiate IA from IC, combination of BG
data with imaging, culture, and histopath-
ologic data allows an etiological diagnosis
in most cases. Moreover, in patients with
positive screening results for BG, genus-
specific fungal markers (i.e., galactoman-
nan for Aspergilus species [3] and man-
nan/antimannan for Candida species [4])
may contribute to the differentiation of IA
from IC. Because several treatment op-
tions that are active against both fungi are
now available, therapeutic decisions are
less dependent on an immediate etiolog-
ical diagnosis [5]. A positive BG result may
trigger the initiation of antifungal therapy.
The complementary investigations may
then allow its adjustment. The similar
overall survival rates for patients with IA
(93%) and IC (89%) in our study support
the efficacy of the initial empirical anti-
fungal strategy.
With regard to the diagnostic perfor-
mance of BG, we observed similar sensi-
tivities, specificities, and positive and neg-
ative predictive values for IA (0.60, 0.96,
0.64, and 0.95, respectively) and IC (0.59,
0.96, 0.67, and 0.94, respectively). The me-
dian time elapsed from fever onset to pos-
itive BG result was also similar (median
time, 0 days; range, 25 to 19 days for
IA, median time, 2 days, range 1 to 16
days for IC). These results support the ef-
ficiency of BG for early detection of both
IA and IC. However, as pointed out by
Pasqualotto and Sukiennik [1], the me-
dian time to the peak BG level in IA (me-
dian time, 3 days; range, 25 to 25 days)
was possibly shorter than for IC (median
time, 12 days; range, 1–46 days). The ki-
netics of other fungal markers is influ-
enced by the timing of antifungal therapy.
Ongoing treatment or prophylaxis may re-
sult in early and low peaks, whereas late
start is associated with delayed and higher
peaks [6]. In our study, the use of a Can-
dida-specific prophylaxis (fluconazole in
one-fourth of IA and IC cases) did not
result in a higher BG sensitivity in IA than
in IC. Moreover, the median time elapsed
from fever onset to initiation of antifungal
therapy was similar for IA (median time,
1 day; range,13 to 13 days) and IC (me-
dian time, 3 days; range, 0–10 days). One
might speculate that the early peak in IA
and later peak in IC could reflect different
pathogeneses. The microbial load may in-
deed differ: single pulmonary lesions were
documented in IA, whereas multiple he-
patosplenic lesions suggesting hematoge-
nous dissemination were documented in
IC. It remains to be determined whether
the concomitance of late BG peak and
neutrophil recovery in IC might reflect the
reaction induced by the immune resto-
ration typically associated with the radi-
ological appearance of organ abscesses.
Because of the small sample size, no firm
conclusion can be drawn from our study
[2] about the different kinetics of BG in
IA and IC.
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Dr. William H. Stewart:
Mistaken or Maligned?
To the Editor—Dr. William H. Stewart
was the US Surgeon General during 1965–
1969 [1]. Despite his significant accom-
plishments, Dr. Stewart is remembered
primarily for his infamous statement: “It
is time to close the book on infectious
diseases, and declare the war against pes-
tilence won” [2]. Depending on the
source, the quote is dated to 1967 or 1969.
Infectious diseases specialists, including
myself [3, 4], have repeated this quote in-
numerable times to underscore how
wrong it was.
I have spent the past 5 years seeking the
primary source for his often-maligned
quote, with no success. And I am not the
only one. The US Public Health Service
Web site informs us that “Although this
remark has often been cited in the liter-
ature, the Office of the PHS Historian has
never been able to locate the source of the
statement, or to confirm that Dr. Stewart
actually made such a comment. We have
asked Dr. Stewart about it, and he cannot
recall whether or not he made this state-
ment” [2].
Virtually every reference to the state-
ment is a secondary citation, and many of
these secondary citations are circular (i.e.,
they reference one another rather than a
primary source). The only primary ref-
erence to this statement, listed in a book
about emerging infections [5], regards a
speech given by Dr. Stewart at the 65th
Annual Meeting of the Association of State
and Territorial Health Officers in 1967 [6].
However, the speech contains nothing
even remotely resembling the alleged
quote. Quite to the contrary, Dr. Stewart
actually said, “Warning flags are still flying
in the communicable disease field….
While we are engaged in taking on new
duties…we cannot and must not lose sight
of our traditional program responsibili-
ties” (p. 4).
It is difficult to believe that a Surgeon
General who was concerned about the tra-
ditional public health responsibility to de-
fend against communicable diseases
would declare that the era of infectious
diseases had come to a close. It appears
that Dr. Stewart’s now-legendary quote
may be a medical “urban legend.”
Nevertheless, Dr. Anthony Fauci has as-
sured us that the belief that infectious dis-
eases had been conquered was widespread
in the 1960s and 1970s [7]. Furthermore,
in 1978, one of the world’s leaders in in-
fectious diseases, Dr. Robert Petersdorf,
commented that, “Even with my great
personal loyalty to Infectious Disease, I
cannot conceive of the need for 309 more
[graduating trainees in] infectious dis-
ease…unless they spend their time cul-
turing each other” [8, p. 630]. As late as
1985, Dr. Petersdorf had not changed his
mind; at the Infectious Diseases Society of
America’s annual meeting that year, he
stated that “the millennium where fellows
in infectious disease will culture one an-
other is almost here” [9].
If anyone is aware of a real primary
citation to Dr. Stewart’s quote, I and oth-
ers would be extremely interested in hear-
ing from you. Failing that, perhaps it is
time to replace Dr. Stewart’s possibly
apocryphal quotation with citations from
verifiable sources, such as Dr. Fauci [7] or
Dr. Petersdorf [8, 9].
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Confounding May Lead
to Overestimation of
Pneumococcal
Polysaccharide Vaccine
Effectiveness among
HIV-Infected Individuals
To the Editor—In a recently published
observational study, Rodriguez-Barradas
et al. [1] found that vaccination of HIV-
